NCT05505838No Longer Available不适用
Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With Cardiomyopathy
Alnylam Pharmaceuticals20 个研究点 分布在 1 个国家开始时间: 2022年8月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 20
研究概览
简要总结
The objective of the study is to assess the long-term safety of patisiran in patients with ATTR amyloidosis with cardiomyopathy as assessed by a review of adverse events (AEs).
详细描述
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented diagnosis of ATTR amyloidosis with cardiomyopathy, classified as either hATTR amyloidosis with cardiomyopathy or wtATTR amyloidosis with cardiomyopathy; AND
- •Had an inadequate response to or could not tolerate standard of care, in the opinion of the investigator.
- •Is not eligible for on-label use of commercial patisiran in the opinion of the investigator.
排除标准
- •New York Heart Association (NYHA) Class IV
- •NYHA Class III AND ATTR amyloidosis disease Stage 3 (defined as both N-terminal prohormone B-type natriuretic peptide (NT-proBNP) >3000 ng/L and estimated glomerular filtration rate [eGFR] <45 ml/min/1.73 m^2). [Gillmore 2018]
- •Current or future participation in another investigational device or drug study, scheduled to occur during this study, or has received an investigational agent or device within 30 days (or 5 half-lives of the investigational drug, whichever is longer) prior to dosing (Day 1). Patients who have previously participated in a gene therapy trial for hATTR amyloidosis.
- •Patients currently enrolled in, eligible for inclusion in, or who have dropped out of an ongoing interventional (therapeutic) clinical trial related to ATTR amyloidosis.
研究者
研究点 (20)
Loading locations...
相似试验
Approved For Marketing
不适用
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, FamilialFamilial Amyloid PolyneuropathiesAmyloid NeuropathiesAmyloidosis, Hereditary, Transthyretin-RelatedNCT02939820Alnylam Pharmaceuticals
已完成
3 期
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated AmyloidosisTTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, FamilialFamilial Amyloid PolyneuropathiesAmyloid NeuropathiesAmyloidosis, Hereditary, Transthyretin-RelatedNCT01960348Alnylam Pharmaceuticals225
已完成
3 期
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)Transthyretin Amyloidosis (ATTR) With CardiomyopathyNCT03997383Alnylam Pharmaceuticals360
已完成
3 期
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver TransplantAmyloidosis, FamilialTransthyretin AmyloidosisNCT03862807Alnylam Pharmaceuticals24
已完成
2 期
Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 DiabetesBeta Cell PreservationType 1 DiabetesNCT01661192Rabin Medical Center12